Organic and Mutagenic Impurities in Pharma

About This White Paper

Impurities can arise throughout the pharmaceutical lifecycle, from synthesis and manufacturing to storage and degradation. While some may have limited impact, others can pose significant toxicological risks, making their identification, characterization and control essential to both product quality and patient safety.

This white paper explores the different types and sources of pharmaceutical impurities, with a particular focus on organic and mutagenic impurities. It explains how guidelines such as ICH Q3A, Q3B and M7 provide a framework for establishing acceptable levels, evaluating impurities that exceed defined limits and managing potential mutagenic risks.

You'll also discover how toxicological assessment supports impurity qualification, from experimental studies and existing scientific data to computational approaches such as QSAR and Read-Across. Together, these tools help determine safe exposure levels and support a robust, science-based approach to impurity control.

Key Takeaways

✓ Understand Where Pharmaceutical Impurities Come From. Explore how synthesis, degradation, raw materials, residual solvents and manufacturing processes can contribute to a medicinal product's impurity profile.

✓ Navigate the Key ICH Guidelines for Impurity Control. Understand the role of ICH Q3A and Q3B for organic impurities and ICH M7 for the assessment and control of mutagenic impurities.

✓ Assess and Qualify Impurities Above Established Limits. Learn what happens when an impurity exceeds an established threshold and how toxicological evidence can be used to establish whether it is safe for patients.

✓ Address the Specific Risks of Mutagenic Impurities. Discover how ICH M7 classifies mutagenic impurities and how concepts such as structural alerts and the Threshold of Toxicological Concern support their evaluation and control.

✓ Build a Robust Toxicological Assessment. Explore how experimental studies, epidemiological data and computational modelling can be combined to characterize potential risks and establish safe exposure levels.

✓ Use QSAR and Read-Across When Data Is Limited. Learn how computational toxicology can help predict biological activity and toxicity based on molecular structure, potentially reducing the need for additional experimental testing.